AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Core Insights - AbbVie announced positive topline results from a Phase 1 study of ABBV-295, a long-acting amylin analog, indicating its potential as a differentiated treatment for chronic weight management [1] - The study demonstrated a favorable tolerability profile with no serious adverse events reported, and clinically meaningful body weight reductions were observed [1] Study Results - ABBV-295 showed a dose-dependent reduction in body weight, with least-squares mean percentage changes ranging from -7.75% to -9.79% at week 12 for weekly dosing, and -7.86% to -9.73% at week 13 for every other week and monthly dosing [1] - In comparison, the placebo group showed minimal weight change of -0.26% at week 12 and -0.25% at week 13 [1] Mechanism and Development - ABBV-295 operates through a non-incretin-based mechanism, distinct from existing therapies like GLP-1 and GIP receptor agonists, targeting amylin and calcitonin receptors to aid in appetite suppression and gastric emptying delay [1] - The study enrolled 76 participants, primarily male (88.3%), and tested various doses (2-14 mg) and dosing frequencies [1] Future Outlook - AbbVie plans to present full data from the study at a future scientific conference, reinforcing the potential of ABBV-295 as a novel therapeutic option for obesity [1]